Diagnosis and management of aspergillosis in the Netherlands: a national survey

Pieter P. A. Lestrade; Jacques F. Meis; Jan P. Arends; Martha T. van der Beek; Els de Brauwer; Karin van Dijk; Sabine C. de Greeff; Pieter-Jan Haas; Caspar J. Hodiamont; Ed J. Kuijper; Tjalling Leenstra; Anouk E. Muller; Astrid Oude Lashof; Bart J. Rijnders; Eveline Roelofsen; Wouter Rozemeijer; Mathijs Tersmette; Elizabeth M. Terveer; Cees M. Verduin; Maurice J. H. M. Wolfhagen; Willem J. G. Melchers; Paul E. Verweij

doi:10.1111/myc.12440

Diagnosis and management of aspergillosis in the Netherlands: a national survey

Pieter P. A. Lestrade, Jacques F. Meis, Jan P. Arends, Martha T. van der Beek, Els de Brauwer, Karin van Dijk, Sabine C. de Greeff, Pieter-Jan Haas, Caspar J. Hodiamont, Ed J. Kuijper, Tjalling Leenstra, Anouk E. Muller, Astrid Oude Lashof, Bart J. Rijnders, Eveline Roelofsen, Wouter Rozemeijer, Mathijs Tersmette, Elizabeth M. Terveer, Cees M. Verduin, Maurice J. H. M. WolfhagenWillem J. G. Melchers, Paul E. Verweij^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

A survey of diagnosis and treatment of invasive aspergillosis was conducted in eight University Medical Centers (UMCs) and eight non-academic teaching hospitals in the Netherlands. Against a background of emerging azole resistance in Aspergillus fumigatus routine resistance screening of clinical isolates was performed primarily in the UMCs. Azole resistance rates at the hospital level varied between 5% and 10%, although rates up to 30% were reported in high-risk wards. Voriconazole remained first choice for invasive aspergillosis in 13 out of 16 hospitals. In documented azole resistance 14 out of 16 centres treated patients with liposomal amphotericin B.

Original language	English
Pages (from-to)	101-107
Number of pages	7
Journal	Mycoses
Volume	59
Issue number	2
DOIs	https://doi.org/10.1111/myc.12440
Publication status	Published - Feb 2016

Keywords

Aspergillosis
azole resistance
treatment

Access to Document

10.1111/myc.12440

Cite this

Lestrade, P. P. A., Meis, J. F., Arends, J. P., van der Beek, M. T., de Brauwer, E., van Dijk, K., de Greeff, S. C., Haas, P.-J., Hodiamont, C. J., Kuijper, E. J., Leenstra, T., Muller, A. E., Oude Lashof, A., Rijnders, B. J., Roelofsen, E., Rozemeijer, W., Tersmette, M., Terveer, E. M., Verduin, C. M., ... Verweij, P. E. (2016). Diagnosis and management of aspergillosis in the Netherlands: a national survey. Mycoses, 59(2), 101-107. https://doi.org/10.1111/myc.12440

@article{5f5289dbd3234eabb82a1c62acad2036,

title = "Diagnosis and management of aspergillosis in the Netherlands: a national survey",

abstract = "A survey of diagnosis and treatment of invasive aspergillosis was conducted in eight University Medical Centers (UMCs) and eight non-academic teaching hospitals in the Netherlands. Against a background of emerging azole resistance in Aspergillus fumigatus routine resistance screening of clinical isolates was performed primarily in the UMCs. Azole resistance rates at the hospital level varied between 5% and 10%, although rates up to 30% were reported in high-risk wards. Voriconazole remained first choice for invasive aspergillosis in 13 out of 16 hospitals. In documented azole resistance 14 out of 16 centres treated patients with liposomal amphotericin B.",

keywords = "Aspergillosis, azole resistance, treatment",

author = "Lestrade, {Pieter P. A.} and Meis, {Jacques F.} and Arends, {Jan P.} and {van der Beek}, {Martha T.} and {de Brauwer}, Els and {van Dijk}, Karin and {de Greeff}, {Sabine C.} and Pieter-Jan Haas and Hodiamont, {Caspar J.} and Kuijper, {Ed J.} and Tjalling Leenstra and Muller, {Anouk E.} and {Oude Lashof}, Astrid and Rijnders, {Bart J.} and Eveline Roelofsen and Wouter Rozemeijer and Mathijs Tersmette and Terveer, {Elizabeth M.} and Verduin, {Cees M.} and Wolfhagen, {Maurice J. H. M.} and Melchers, {Willem J. G.} and Verweij, {Paul E.}",

year = "2016",

month = feb,

doi = "10.1111/myc.12440",

language = "English",

volume = "59",

pages = "101--107",

journal = "Mycoses",

issn = "0933-7407",

publisher = "Wiley",

number = "2",

}

Lestrade, PPA, Meis, JF, Arends, JP, van der Beek, MT, de Brauwer, E, van Dijk, K, de Greeff, SC, Haas, P-J, Hodiamont, CJ, Kuijper, EJ, Leenstra, T, Muller, AE, Oude Lashof, A, Rijnders, BJ, Roelofsen, E, Rozemeijer, W, Tersmette, M, Terveer, EM, Verduin, CM, Wolfhagen, MJHM, Melchers, WJG & Verweij, PE 2016, 'Diagnosis and management of aspergillosis in the Netherlands: a national survey', Mycoses, vol. 59, no. 2, pp. 101-107. https://doi.org/10.1111/myc.12440

TY - JOUR

T1 - Diagnosis and management of aspergillosis in the Netherlands: a national survey

AU - Lestrade, Pieter P. A.

AU - Meis, Jacques F.

AU - Arends, Jan P.

AU - van der Beek, Martha T.

AU - de Brauwer, Els

AU - van Dijk, Karin

AU - de Greeff, Sabine C.

AU - Haas, Pieter-Jan

AU - Hodiamont, Caspar J.

AU - Kuijper, Ed J.

AU - Leenstra, Tjalling

AU - Muller, Anouk E.

AU - Oude Lashof, Astrid

AU - Rijnders, Bart J.

AU - Roelofsen, Eveline

AU - Rozemeijer, Wouter

AU - Tersmette, Mathijs

AU - Terveer, Elizabeth M.

AU - Verduin, Cees M.

AU - Wolfhagen, Maurice J. H. M.

AU - Melchers, Willem J. G.

AU - Verweij, Paul E.

PY - 2016/2

Y1 - 2016/2

N2 - A survey of diagnosis and treatment of invasive aspergillosis was conducted in eight University Medical Centers (UMCs) and eight non-academic teaching hospitals in the Netherlands. Against a background of emerging azole resistance in Aspergillus fumigatus routine resistance screening of clinical isolates was performed primarily in the UMCs. Azole resistance rates at the hospital level varied between 5% and 10%, although rates up to 30% were reported in high-risk wards. Voriconazole remained first choice for invasive aspergillosis in 13 out of 16 hospitals. In documented azole resistance 14 out of 16 centres treated patients with liposomal amphotericin B.

AB - A survey of diagnosis and treatment of invasive aspergillosis was conducted in eight University Medical Centers (UMCs) and eight non-academic teaching hospitals in the Netherlands. Against a background of emerging azole resistance in Aspergillus fumigatus routine resistance screening of clinical isolates was performed primarily in the UMCs. Azole resistance rates at the hospital level varied between 5% and 10%, although rates up to 30% were reported in high-risk wards. Voriconazole remained first choice for invasive aspergillosis in 13 out of 16 hospitals. In documented azole resistance 14 out of 16 centres treated patients with liposomal amphotericin B.

KW - Aspergillosis

KW - azole resistance

KW - treatment

U2 - 10.1111/myc.12440

DO - 10.1111/myc.12440

M3 - Article

C2 - 26648179

SN - 0933-7407

VL - 59

SP - 101

EP - 107

JO - Mycoses

JF - Mycoses

IS - 2

ER -